Achieve Life Sciences, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Achieve Life Sciences, Inc. (ACHV) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.59 million as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-24
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.59M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.53M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.13M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.04M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $1.59M 10-K · filed 2026-03-24 |
| 2024-12-31 | $1.53M 10-K · filed 2026-03-24 |
| 2023-12-31 | $1.13M 10-K · filed 2025-03-11 |
| 2022-12-31 | $1.04M 10-K · filed 2024-03-28 |
| 2021-12-31 | $702.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $466.00K 10-K · filed 2021-03-11 |
| 2019-12-31 | $315.00K 10-K · filed 2021-03-11 |
| 2018-12-31 | $171.00K 10-K · filed 2020-03-13 |
| 2017-12-31 | $51.00K 10-K · filed 2019-03-14 |
| 2016-12-31 | $3.74M 10-K · filed 2017-02-23 |
| 2015-12-31 | $3.45M 10-K · filed 2017-02-23 |
| 2014-12-31 | $3.16M 10-K · filed 2016-03-09 |
| 2013-12-31 | $2.58M 10-K · filed 2015-03-26 |
| 2012-12-31 | $2.08M 10-K · filed 2014-03-11 |
| 2011-12-31 | $1.63M 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |